Sartar was awarded a USA patent for use of anagrelide in cancer therapy.
Author: ollipulkka
Sartar won HealthBIO pitching competition 9.10.2017
Sartar Therapeutics participated to the HealthBIO pitching competition and won it.
http://turkusciencepark.com/spark-uutiset/1673/suomalaisen-life-science-alan-vienti-vahvassa-ka/
BIO-Europe Berlin November 6–8, 2017
Sartar will participate in the Next Generation tract company presentations in the BIO-Europe conference at Wednesday 8th of November.
https://ebdgroup.knect365.com/bioeurope/
HealthBIO Seminar and Partnering Event in Turku 5-6.9.2017
Sartar participates in HealthBIO partnering event.
Sartar was chosen to SPARK Finland program starting at 2.5.2017
SPARK Finland program is designed to increase the maturity of academic and clinical discoveries towards practical solutions in the life science and health tech space.